Decision aids and prostate cancer: how useful are they?

Your sitemaster has long had concerns about the real value of decision aids in helping men to think about and come to conclusions about controversial issues in the diagnosis and management of prostate cancer. … READ MORE …

Strategies to maintain sexual function post-treatment for prostate cancer

A research group at the University of Otago in New Zealand is continuing to investigate how men treated for prostate cancer deal with sexual dysfunction. We have helped them with this before and will continue to do so. … READ MORE …

3-year outcomes of men on AS in US community urology settings

To date we have seen very few data on the long-term follow-up of men in the US being initially managed on active surveillance (AS) after diagnosis with prostate cancer out in the “real world” of community urology practice. … READ MORE …

Patient satisfaction and the management of localized prostate cancer

A recent paper from a large Swedish research group has addressed patient satisfaction and the management of localized prostate cancer — with a specific, inclusive focus on the satisfaction of men initially managed on active surveillance. … READ MORE …

AS in practice in a specific US community setting

In a presentation at the ASCO annual meeting, Dr. Ronald Chen reported that just 32 percent of newly diagnosed men who were initially managed on active surveillance (AS) in North Carolina between 2011 and 2013 were actually managed in compliance with guideline recommended monitoring. … READ MORE …

Gallium-68 PSMA vs. fluorine-18 fluciclovine PET/CT scans

According to a presentation given yesterday at the ASCO meeting here in Chicago, PET/CT scanning with 68Ga-PSMA-11 is more accurate than 18F-fluciclovine PET/CT at detecting recurrent prostate cancer in men with early biochemical recurrence following radical prostatectomy. … READ MORE …

Data from the TAXOMET trial also presented at ASCO

Data from a small, Phase II, French trial known as the TAXOMET trial were also presented yesterday at the ASCO meeting. … READ MORE …